Associations - MET amplification

BIOMARKER:

MET amplification

Entrez ID:

4233

Related biomarkers:

‹

›

MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline Tumori - 3 weeks crizotinib Sensitive : A2 Tumori - 3wk
MET amplification MET amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	crizotinib Sensitive: C3 – Early Trials Target Oncol - 3 weeks crizotinib Sensitive : C3 Target Oncol - 3wk
MET amplification MET amplification	GastroEsophageal Cancer GastroEsophageal Cancer	crizotinib Sensitive: C3 – Early Trials Target Oncol - 3 weeks crizotinib Sensitive : C3 Target Oncol - 3wk
MET amplification MET amplification	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials Tumori - 3 weeks crizotinib Sensitive : C3 Tumori - 3wk
MET amplification MET amplification	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification MET amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	crizotinib + bevacizumab Sensitive: C2 – Inclusion Criteria crizotinib + bevacizumab Sensitive : C2
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	SCC244 Sensitive: C2 – Inclusion Criteria SCC244 Sensitive : C2
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria gefitinib + CT053PTSA Sensitive : C2
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	osimertinib + HMPL-504 Sensitive: C2 – Inclusion Criteria osimertinib + HMPL-504 Sensitive : C2
MET amplification MET amplification	Lung Cancer Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	crizotinib + osimertinib Sensitive: C2 – Inclusion Criteria crizotinib + osimertinib Sensitive : C2
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: C2 – Inclusion Criteria capmatinib Sensitive : C2
MET amplification MET amplification	Gastric Cancer Gastric Cancer	HMPL-504 Sensitive: C2 – Inclusion Criteria HMPL-504 Sensitive : C2
MET amplification MET amplification	Renal Cell Carcinoma RCC	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MET amplification MET amplification	Gallbladder Cancer Gallbladder Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3
MET amplification MET amplification	Colorectal Cancer CRC	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3
MET amplification MET amplification	Gastric Cancer Gastric Cancer	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	gefitinib + HMPL-504 Sensitive: C3 – Early Trials gefitinib + HMPL-504 Sensitive : C3
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
MET amplification MET amplification	Solid Tumor Solid Tumor	TQ-B3101 Sensitive: C3 – Early Trials TQ-B3101 Sensitive : C3
MET amplification MET amplification	Lung Adenocarcinoma LUAD	crizotinib + osimertinib Sensitive: C3 – Early Trials crizotinib + osimertinib Sensitive : C3
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
MET amplification MET amplification	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES